Thank you for standing with the PDCD community and adding your voice to this important petition. With more than 18,000 signatures, you helped show the FDA just how urgent the need is for children who rely on access to DCA.
Today, Saol Therapeutics announced that the FDA has granted a Type A meeting on December 18th to review new and expanded data and discuss a potential path forward. This meeting is an encouraging step — and a direct testament to the strength, compassion, and visibility of this community.
As we head into the holiday season, our families are holding onto one simple wish: that the path toward a life-changing treatment becomes clear. Your support is helping make that hope visible.
We expect to learn more in January about what the future could look like and will continue to keep you updated.
In the meantime, please keep speaking out, sharing your stories, and helping ensure the FDA understands what is at stake for families living with PDCD. Your advocacy matters. It is being heard. And it must continue.